Lurbinectedin is a relatively new drug that has shown promise in the treatment of certain types of cancer. According to Drug Patent Watch [1], the patent for lurbinectedin is set to expire in 2037. This means that the drug is still under patent protection, and there are no generic versions of the drug available on the market. As a result, the cost of lurbinectedin is likely to be higher than other drugs that have been on the market for a longer period of time.
A study published in Value in Health [2] analyzed the cost-effectiveness of lurbinectedin compared to other treatments for small cell lung cancer (SCLC). The study found that lurbinectedin was more effective than standard chemotherapy for SCLC, but it was also more expensive. The study estimated that the cost per quality-adjusted life year (QALY) gained with lurbinectedin was $227,000, which is higher than the commonly accepted threshold for cost-effectiveness in the United States.
Another study published in the Journal of Clinical Oncology [3] compared the cost-effectiveness of lurbinectedin to other treatments for relapsed SCLC. The study found that lurbinectedin was more effective than other treatments, but it was also more expensive. The study estimated that the cost per QALY gained with lurbinectedin was $301,000, which is also higher than the commonly accepted threshold for cost-effectiveness in the United States.
In summary, the cost of lurbinectedin is likely to be higher than other drugs that have been on the market for a longer period of time, as it is still under patent protection. Studies have shown that lurbinectedin is more effective than standard chemotherapy and other treatments for certain types of cancer, but it is also more expensive. The cost per QALY gained with lurbinectedin is higher than the commonly accepted threshold for cost-effectiveness in the United States.
Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.valueinhealthjournal.com/article/S1098-3015(19)32711-1/fulltext
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/